Japan PPI inflation slips to 11-mth low in July
On Friday, BofA Securities issued a downgrade for Voya Financial (NYSE:VOYA) stock, moving its rating from Neutral to Underperform. The firm also adjusted the price target downward to $71 from the previous $79. This move reflects concerns over the company’s earnings projections and cash flow generation capabilities. According to InvestingPro data, the stock currently trades at a P/E ratio of 11.02 and appears undervalued based on comprehensive Fair Value analysis. Notably, six analysts have recently revised their earnings expectations downward for the upcoming period.
BofA Securities highlighted Voya Financial’s management’s guidance, which anticipates a free cash flow generation of approximately $700 million after accounting for expenses related to expanding its lead management and disability administration capabilities. This projection is based on the expectation of a 90-100% free cash flow conversion from income, suggesting an income range of $700-780 million for the year 2025. This would translate to an earnings per share (EPS) of $7.10 to $7.90, which is below the consensus estimate of $8.14 EPS. InvestingPro analysis shows the company maintains strong financial health with an overall score of "GOOD," supported by robust liquidity metrics and consistent dividend payments for 13 consecutive years.
The analysts expressed skepticism regarding the company’s ability to achieve the sub-$8 EPS figure for 2025, even when considering management’s guidance. They indicated that the difficulty lies in finding sufficiently low margins to support the lower EPS forecast. According to BofA Securities, the lower EPS estimate presents a downside to their already reduced EPS forecast for 2025.
The report also pointed out that 2025 is viewed as a "reset" year for Voya Financial. This perspective is due to the anticipated changes and priorities set by the new CFO, Mike Katz, and the new Head of Health, Jay Kaduson. Their leadership is expected to influence the company’s strategic direction and financial performance.
Investors and market watchers will be keeping a close eye on Voya Financial’s financial performance as it navigates through the forecasted reset year and implements the strategies of its new leadership team. The revised rating and price target from BofA Securities serve as an indicator of the firm’s current stance on the company’s stock. InvestingPro subscribers can access additional insights through the comprehensive Pro Research Report, which includes detailed analysis of Voya’s financial metrics, growth prospects, and peer comparisons.
In other recent news, Voya Financial reported strong fourth-quarter earnings, with earnings per share (EPS) of $1.40, surpassing the analyst consensus of $1.27, and revenue reaching $2.01 billion against the forecasted $1.88 billion. Despite these positive results, the company disclosed preliminary fourth-quarter figures that fell short of long-term expectations, with alternative investment income and prepayment fees estimated to be $8 million to $16 million below projections. Voya Financial’s management highlighted challenges in the Health Solutions segment, particularly in the Stop Loss business, while expressing optimism for improved profitability in 2025.
Morgan Stanley (NYSE:MS) recently upgraded Voya Financial’s stock rating to Overweight, citing confidence in the company’s long-term growth strategy and setting a new price target of $87.00. In contrast, Barclays (LON:BARC) downgraded the stock to Equal Weight with a price target of $75.00, pointing to concerns about weaker expected earnings power and limited valuation upside. Similarly, Wells Fargo (NYSE:WFC) adjusted its rating to Equal Weight, expressing caution over the company’s stop loss performance and revising the price target to $76.00. These developments reflect varying analyst perspectives on Voya Financial’s future performance amidst its strategic challenges and growth opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.